Clinical Trial Update: Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates olutasidenib plus azacitidine, followed by olutasidenib maintenance, for IDH1-mutated acute myeloid leukemia in patients previously…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Olutasidenib (olutasidenib)

Snippet

Sponsor: University of California, Davis | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING